Sagimet Biosciences
SGMT
8.72
-0.16
-1.80%
Sagimet Biosciences
US · SGMT
#3599 by market cap
Listed 2023
8.72
-0.16
-1.80%
Live - 5344 symbols - heartbeat 402s ago
· 2026-10-08 10:00
Pre-market
8.83
-0.56%
After-hours
8.88
0.00%
- Market cap
- 618.32M
- P/E (TTM)i
- -6.92
- P/Bi
- 2.41
- EPSi
- -1.58
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on SGMT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 10.9 percentage points.
Institutional ownership
- Held by institutions
- 74.39% -10.94pp
- Institutions
- 138
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund34.04%
Mutual Fund29.09%
VC/PE Fund6.21%
Public Company4.43%
Individual/Insider0.96%
Private Company0.23%
Insurance Company0.18%
Government Pension Fund0.10%
Endowment Fund0.10%
Other24.66%
Top holders as of 2026-06-30
BlackRock
9.27% · 6.58M sh
Balyasny Asset Management L.P.
5.11% · 3.63M sh
Woodline Partners LP
4.23% · 3.00M sh
Vanguard Capital Management, LLC
4.18% · 2.97M sh
Silverarc Capital Management, LLC
4.13% · 2.93M sh
Caligan Partners, LP
3.53% · 2.50M sh
BVF Partners L.P.
3.53% · 2.50M sh
Affinity Asset Advisors, LLC
3.52% · 2.50M sh
Federated Hermes, Inc.
2.94% · 2.09M sh
Great Point Partners, LLC
2.86% · 2.03M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 13 sells
| Name | Role | Stake |
|---|---|---|
| David Happel | Chief Executive Officer | 0.52% |
| Beth Seidenberg | Independent Director | 0.19% |
| Elizabeth Rozek | Chief Compliance Officer | 0.14% |
| Eduardo Martins | Chief Medical Officer | 0.05% |
| George Kemble | Executive Chairperson | 0.03% |
| Merdad Parsey | Independent Director | 0.02% |
| Thierry Chauche | Chief Financial Officer | 0.00% |
| Timothy Walbert | Director | 0.00% |
| Elizabeth Grammer | Independent Director | -- |
| Anne Phillips | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-13 | George Kemble | Executive Chairperson | Derivative Exercise and Sale | -350,987 | $6.36–10.23 |
| 2026-08-10 | George Kemble | Executive Chairperson | Derivative Exercise and Sale | -20,206 | $6.36–9.95 |
| 2026-07-19 | George Kemble | Executive Chairperson | Automatic Disposition | -18,844 | $7.46 |
| 2026-07-19 | David Happel | Chief Executive Officer | Open Market Disposition | -64,051 | $7.76 |
| 2026-07-19 | Elizabeth Rozek | Chief Compliance Officer | Open Market Disposition | -10,545 | $7.76 |
| 2026-06-11 | Beth Seidenberg | Independent Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | Elizabeth Grammer | Independent Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | George Kemble | Executive Chairperson | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | Anne Phillips | Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | Paul Hoelscher | Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | Jennifer Jarrett | Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-05-27 | David Happel | Chief Executive Officer | Other Derivative Acquisition | +300,000 | $7.27 |
| 2026-05-27 | Elizabeth Rozek | Chief Compliance Officer | Other Derivative Acquisition | +100,000 | $7.27 |
| 2026-05-27 | Andreas Grauer | Chief Medical Officer | Other Derivative Acquisition | +35,000 | $7.27 |
| 2026-05-27 | Thierry Chauche | Chief Financial Officer | Other Derivative Acquisition | +50,000 | $7.27 |
| 2026-04-19 | Andreas Grauer | Chief Medical Officer | Other Derivative Acquisition | +264,759 | $6.44 |
| 2026-02-18 | Eduardo Martins | Chief Medical Officer | Other Acquisition | +44,000 | -- |
| 2026-02-18 | Eduardo Martins | Chief Medical Officer | Other Derivative Acquisition | +88,000 | $5.38 |
| 2026-02-18 | David Happel | Chief Executive Officer | Other Acquisition | +128,000 | -- |
| 2026-02-18 | David Happel | Chief Executive Officer | Other Derivative Acquisition | +256,000 | $5.38 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:18 · For reference only, not investment advice and not tailored to your situation.